At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,067 enrolled
Drug / intervention
biomarkers, MRI and CSFbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Plasma Abeta Peptides and the Risk of Alzheimer's Disease. Diagnostic Performance and Predictive and Prognostic Values of Measurements of Plasma Amyloid Peptides Concentrations for the Diagnosis of Alzheimer's Disease
In Brief
A clinical study evaluating biomarkers, MRI and CSF for Alzheimer's Disease and Mild Cognitive Impairment. Completed, enrolled 1,067 participants across 1 site.
Detailed Summary
The aim of this study is to examine the relationship between plasma putative biomarkers for Alzheimer's disease (i.e. Ab40 amyloid and total Ab42 amyloid, free, bound, free/bound, truncated, sAPPα) and : * the risk of conversion of individuals with Mild Cognitive Impairment (MCI) into Alzheimer's disease (AD), * the Alzheimer's disease progression rate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Mild Cognitive Impairment
CountriesFrance
CollaboratorsURC-CIC Paris Descartes Necker Cochin
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedMar 2011
Primary CompletionFeb 2015
Study CompletionMar 2018
TodayJul 2026
First PostedMar 15, 2011
Enrollment StartSep 3, 2010
Primary CompletionFeb 26, 2015
Study CompletionMar 16, 2018
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 15.3 years ago
Interventions
biomarkers, MRI and CSFbiological
MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0